Page last updated: 2024-10-30

losartan and Ambulation Difficulty

losartan has been researched along with Ambulation Difficulty in 3 studies

Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position

Research Excerpts

ExcerptRelevanceReference
"The Enabling Reduction of Low-grade Inflammation in Seniors (ENRGISE) Pilot Study is a multicenter randomized clinical trial examining the feasibility of testing whether omega-3 fish oil (ω-3) and the angiotensin receptor blocker losartan alone or in combination can reduce inflammation and improve walking speed in older adults with mobility impairment."5.30The Enabling Reduction of Low-Grade Inflammation in Seniors (ENRGISE) Pilot Study: Screening Methods and Recruitment Results. ( Ambrosius, WT; Anton, SD; Cauley, JA; Domanchuk, K; Fielding, RA; Kennedy, K; Kritchevsky, SB; Lovato, L; Manini, TM; McDermott, MM; Newman, AB; Pahor, M; Stowe, CL; Talton, J; Walkup, M, 2019)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Manini, TM3
Anton, SD3
Beavers, DP2
Cauley, JA3
Espeland, MA1
Fielding, RA3
Kritchevsky, SB3
Leeuwenburgh, C2
Lewis, KH2
Liu, C1
McDermott, MM3
Miller, ME2
Tracy, RP2
Walston, JD1
Radziszewska, B2
Lu, J2
Stowe, C1
Wu, S1
Newman, AB3
Ambrosius, WT3
Pahor, M3
Lovato, L1
Talton, J1
Domanchuk, K1
Kennedy, K1
Stowe, CL2
Walkup, M1
Liu, CK1
Lovato, LC1
Walkup, MP1
Wu, SS1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The ENRGISE (ENabling Reduction of Low-Grade Inflammation in SEniors) Pilot Study[NCT02676466]Phase 2289 participants (Actual)Interventional2016-04-26Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Changes in the Interleukin-6 Level Between Groups

Changes in the Interleukin-6 Level Between the Groups (NCT02676466)
Timeframe: Changes from baseline to month 12

Interventionpg/ml (Mean)
Fish Oil Active0
Fish Oil Placebo-0.1
Losartan Active-0.6
Losartan Placebo3.8
Fish Oil Active + Losartan Active-0.3
Fish Oil Active + Losartan Placebo-0.2
Fish Oil Placebo + Losartan Active-1.4
Fish Oil Placebo + Losartan Placebo-1.0

Isometric Hand Grip Strength

The purpose of this test is to measure the maximum isometric strength of the hand and forearm muscles. Scoring will be taken from the best results of 3 trials. Males scores range from 88 pounds as very poor to 141 pounds as excellent with an average of 105-113 pounds. Females scores range from 44 pounds as very poor to 84 pounds as excellent with an average of 57-65 pounds. (NCT02676466)
Timeframe: 12 months

Interventionpounds (Mean)
Fish Oil Active24.8
Fish Oil Placebo25.3
Losartan Active25.9
Losartan Placebo27.5
Fish Oil Active + Losartan Active22.4
Fish Oil Active + Losartan Placebo19.8
Fish Oil Placebo + Losartan Active27.6
Fish Oil Placebo + Losartan Placebo23.6

Number of Participants Exhibiting Frailty

Frailty will be characterized with Fried criteria developed by Fried et al. that employ self-reported exhaustion, unintentional weight loss, low energy expenditure, slow gait speed, and weak grip strength. Those with >3 of the 5 factors are judged to be frail, those with 1 or 2 factors as pre-frail, and those with no factors as non-frail. (NCT02676466)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Fish Oil Active15
Fish Oil Placebo3
Losartan Active4
Losartan Placebo1
Fish Oil Active + Losartan Active3
Fish Oil Active + Losartan Placebo3
Fish Oil Placebo + Losartan Active1
Fish Oil Placebo + Losartan Placebo1

Number of Participants Experiencing Major Mobility Disability

The 400 meter walk test at usual pace is used to evaluate major mobility disability (MMD), defined as the inability to walk ¼ mile or 400 meters. (NCT02676466)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Fish Oil Active20
Fish Oil Placebo5
Losartan Active4
Losartan Placebo15
Fish Oil Active + Losartan Active4
Fish Oil Active + Losartan Placebo3
Fish Oil Placebo + Losartan Active7
Fish Oil Placebo + Losartan Placebo3

Peak Torque of the Knee Extensor and Flexor Muscles

Peak torque was measured at a rotational speed of 60 degrees per second using a commercially-available Isokinetic Dynamometer (Biodex). Torque was measured during maximal knee extension and flexion reported in Newton Meters. (NCT02676466)
Timeframe: month 12

InterventionNewton meters (Mean)
Fish Oil Active81.3
Fish Oil Placebo77.7
Losartan Active87.6
Losartan Placebo78.6
Fish Oil Active + Losartan Active85.3
Fish Oil Active + Losartan Placebo76.6
Fish Oil Placebo + Losartan Active84.0
Fish Oil Placebo + Losartan Placebo86.1

Short Form Health Survey (SF-36) - Physical Component Score

The Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Range: 0-100. A lower score indicates more disability, i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. (NCT02676466)
Timeframe: month 12

Interventionscore on a scale (Mean)
Fish Oil Active41.9
Fish Oil Placebo42.6
Losartan Active41.8
Losartan Placebo41.3
Fish Oil Active + Losartan Active41.9
Fish Oil Active + Losartan Placebo42.7
Fish Oil Placebo + Losartan Active46.6
Fish Oil Placebo + Losartan Placebo47.9

Short Physical Performance Battery (SPPB)

A low score on the SPPB based on 4 m walk, balance & chair stands tests is a risk factor for disability, institutionalization, morbidity and mortality in initially non-disabled older persons. The summary score and components of the SPPB have good reliability (ICCs range from 0.88 to 0.92). Higher scores are better. Range 0-12. (NCT02676466)
Timeframe: 12 months

Interventionunits on a scale (Mean)
Fish Oil Active8.6
Fish Oil Placebo8.1
Losartan Active8.2
Losartan Placebo8.4
Fish Oil Active + Losartan Active8.6
Fish Oil Active + Losartan Placebo7.3
Fish Oil Placebo + Losartan Active8.5
Fish Oil Placebo + Losartan Placebo9.1

Trials

3 trials available for losartan and Ambulation Difficulty

ArticleYear
ENabling Reduction of Low-grade Inflammation in SEniors Pilot Study: Concept, Rationale, and Design.
    Journal of the American Geriatrics Society, 2017, Volume: 65, Issue:9

    Topics: Aged; Antihypertensive Agents; Double-Blind Method; Eicosapentaenoic Acid; Female; Humans; Inflammat

2017
The Enabling Reduction of Low-Grade Inflammation in Seniors (ENRGISE) Pilot Study: Screening Methods and Recruitment Results.
    The journals of gerontology. Series A, Biological sciences and medical sciences, 2019, 07-12, Volume: 74, Issue:8

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Fatty Acids, Omega-3; Feasibility Studies; Female; H

2019
Effect of Losartan and Fish Oil on Plasma IL-6 and Mobility in Older Persons. The ENRGISE Pilot Randomized Clinical Trial.
    The journals of gerontology. Series A, Biological sciences and medical sciences, 2019, 09-15, Volume: 74, Issue:10

    Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Double-Blind Method; Fatty Acids,

2019